Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Placental implantable disease markers

A placenta accreta and disease technology, applied in the field of placenta accreta disease markers, can solve problems such as no further application, unclear clinical significance, and high technical requirements.

Active Publication Date: 2020-03-31
THE THIRD AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY
View PDF12 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] It has been reported that serum alpha-fetoprotein (AFP) is significantly correlated with placenta accreta, but its specificity is not high, and it has not been developed into a clinically applicable detection kit
Analysis of placental free mRNA in maternal plasma in the first trimester can predict placenta accreta, but it requires high technical means, and there is no further application at present
In addition, studies have reported that fetal cell-free DNA in plasma is elevated in peripheral blood of placenta accreta, but the clinical significance is not clear
Therefore, as of now, there is no mature method for detecting placenta accreta in pregnant women using miRNA molecules in maternal serum

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Placental implantable disease markers
  • Placental implantable disease markers
  • Placental implantable disease markers

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] 1. Materials and equipment

[0040] Kit: MagMAX mirVana Total RNA Isolation Kit

[0041] Instrument model: 7900HT real-time fluorescence quantitative instrument of ABI company

[0042] Chip: miRCURY-Ready-to-Use PCR-Human-panel-I+II-V4.M

[0043] 2. Collection of peripheral blood samples

[0044] After obtaining the informed consent of the pregnant women, the non-anticoagulated peripheral blood serum of suspected cases and the non-anticoagulated peripheral blood serum of normal delivery pregnant women were collected before delivery. After coagulation at room temperature for 30-45 minutes, centrifuge at 4°C at 2000g for 15 minutes. minutes to separate the serum and cells, and then transfer the separated serum to a cryopreservation tube. Store in a -80°C ultra-low temperature freezer. After the samples were collected, 200 μl of serum was melted at 4°C, and centrifuged repeatedly at 2000 g for 10 minutes to completely remove platelets and other precipitates.

[0045] ...

Embodiment 2

[0055] 1. Materials and equipment

[0056] Kit: MagMAX mirVana Total RNA Isolation Kit

[0057] Instrument model: Q-PCR instrument of ABI company

[0058] 2. Collection of peripheral blood samples

[0059] After obtaining the informed consent of the pregnant women, the non-anticoagulated peripheral blood serum of suspected cases and the non-anticoagulated peripheral blood serum of normal delivery pregnant women were collected before delivery. After coagulation at room temperature for 30-45 minutes, centrifuge at 4°C at 2000g for 15 minutes. minutes to separate the serum and cells, and then transfer the separated serum to a cryopreservation tube. Store in a -80°C ultra-low temperature freezer. After the samples were collected, 200 μl of serum was melted at 4°C, and centrifuged repeatedly at 2000 g for 10 minutes to completely remove platelets and other precipitates.

[0060] 3. Extraction of serum total RNA

[0061] According to the method provided by the manufacturer, tot...

Embodiment 3

[0074]Using the same method as in Example 2, the third group of people was tested, and the expression of miR-671-3p was performed on the non-anticoagulated peripheral blood serum collected before delivery from pregnant women with bleeding tendency and normal pregnant women. volume detection. The specific diagnostic results are obtained from the pathological tissue analysis of pregnant women after delivery. The true positive results are confirmed cases of placenta accreta, and the false positive results include cases of placenta previa and preeclampsia. The final number is 20 cases of placenta accreta, 20 cases of placenta previa, 20 cases of preeclampsia, and 20 normal controls.

[0075] Table 2 The multiple of change and P value among different groups in the third batch of population

[0076]

[0077] Ratio: The expression ratio between different groups. PAS: placenta accreta; CON: normal delivery; PP: placenta previa; PE: preeclampsia; *: p<0.05 by t-test between two gr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of molecular diagnosis and medical treatment, in particular to an application of miR-671-3p as a placenta implantable disease marker. The miR-671-3p can be used fordiagnosis of placental implantable diseases, or used for distinguishing placental implantable diseases from preplacenta and preeclampsia, and has important clinical application value.

Description

technical field [0001] The invention relates to the field of molecular diagnostic medicine, in particular to a placenta accreta disease marker. Background technique [0002] Placenta accreta spectrum disorders (PAS) is a pregnancy complication in which placental villi adhere abnormally or invade the myometrium. According to statistics, the incidence rate of PAS among pregnant women in the world is 0.01% to 1.1%, and its mortality rate is about 0.05%, which seriously endangers the life safety of mothers and fetuses. Studies have shown that placenta previa and cesarean section are important independent factors leading to the pathogenesis of PAS, and the increase in its incidence is one of the important factors leading to the gradual increase in the incidence in recent years. The occurrence and development of placenta accreta disease is a complex multifactorial process. Current studies have shown that loss of decidua, abnormal maternal vascular remodeling, and erosion of extra...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6883
CPCC12Q1/6883C12Q2600/158C12Q2600/178
Inventor 余波澜
Owner THE THIRD AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com